AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03990220 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Lactobacillus rhamnosus yoba 2012
Description: Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug.
Study NCT00518557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter Arterial Chemoembolization
Description: The interventional procedure is performed as following steps: 1)transcatheter hepatic arterial angiography(including any feeding arteries to the tumor) is performed under a DSA unit; 2) super selectively catheterizaton of feeding arteries to the tumor is reached; 3)30 mg of Andostatin (Simcere Co. China) mixtured with 5 ml Lipiodol is injected into the tumor via the feeding arteries; 4) followed by 10 mg of Epifubicin mixtured with 5 ml of Lipiodol; 5) All feeding arteries to the tumor are occluded which is confirmed by re-angiography.
Study NCT00518557 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter Arterial Chemoembolization
Description: The interventional procedure is performed as following steps: 1)transcatheter hepatic arterial angiography(including any feeding arteries to the tumor) is performed under a DSA unit; 2) super selectively catheterizaton of feeding arteries to the tumor is reached; 3)30 mg of Andostatin (Simcere Co. China) mixtured with 5 ml Lipiodol is injected into the tumor via the feeding arteries; 4) followed by 10 mg of Epifubicin mixtured with 5 ml of Lipiodol; 5) All feeding arteries to the tumor are occluded which is confirmed by re-angiography.
Study NCT00048828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Participants will receive olanzapine for 12 weeks.
Study NCT00048828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clozapine
Description: Participants will receive 12 weeks of clozapine.
Study NCT02655380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 1
Description: Anesthesia induction is performed with 1 mg ketamine.
Study NCT02655380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 2
Description: Anesthesia induction is performed with 2 mg ketamine.
Study NCT02655380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.
Study NCT02438124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation
Description: The subjects are submitted in one hearing stimulus while they realize a walking test
Study NCT00470106 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive remediation
Description: Computer exercises in attention, memory, and speed of processing.
Study NCT00548886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: We will follow the protocol outlined by Ackerman et al. known as the Mayo protocol4 which is currently used routinely in our electrophysiology laboratory. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes and a twelve-lead electrocardiogram is obtained at time=0 minutes, 5 minutes, and 10 minutes. The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes and the electrocardiogram repeated. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes and electrocardiogram obtained. The epinephrine infusion is then discontinued and measurements are obtained at five minutes and ten minutes after stopping the epinephrine infusion. The total time of procedure will be 35 minutes.
Study NCT04513236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-survey incentive
Description: An incentive of is given in the form of airtime to motivate participants to complete the survey. Participants were sent 0.1X before the were sent a mobile phone survey and an additional 1X after completing the survey.
Study NCT04513236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-survey incentive
Description: An incentive in the form of airtime to motivate participants to complete the survey. Participants were given Bangladeshi Taka or Ugandan Shillings worth of certain airtime for completing the survey.
Study NCT03404882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive/reminder text messaging plus peer support
Description: Regular supportive/reminder text message will be delivered to patients who will also receive face to face and interactive text message support from peer support workers
Study NCT03404882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive/reminder text messaging
Description: Regular supportive/reminder text message will be delivered to patients who will NOT receive any face to face or interactive text message support from peer support workers
Study NCT03404882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer support only
Description: face to face support from peer support workers but no interactive or daily supportive/reminder text messages
Study NCT03735914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Neuralgic patients for which a cryoneurolysis has been indicated, will passed an MRI befor and after the cryoneurolysis to check the presence of the nerve.
Study NCT04203576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FIRE1 System
Description: FIRE1 System
Study NCT01741961 — intervention group
Intervention type: PROCEDURE
Intervention: Ahmed valve
Description: The flexible plate 7 (FP7) model (New World Medical) was implanted in patients with uncontrolled glaucoma.
Study NCT02476227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation using CARTO system
Description: automated algorithm (Visitag)-based vs. manual collection of RF ablation points during AF ablation
Study NCT02476227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation using CARTO system
Description: automated algorithm (Visitag)-based vs. manual collection of RF ablation points during AF ablation
Study NCT05119816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy intervention
Description: Received a customize playlists prepared by a certified music therapist to listening to during KB
Study NCT03680521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib oral capsule administered daily for 6-8 weeks in segments 1 and 2.
Study NCT03680521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab administered as 240 mg IV every 2 weeks for 4-6 weeks in segment 2.
Study NCT02576626 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: indacaterol/glycopyrronium 110/50 Breezhaler®
Study NCT02576626 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Placebo by Breezhaler®
Study NCT02576626 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation
Study NCT02576626 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Placebo by nebulisation
Study NCT04470414 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IgG antibodies immunoassay
Description: Assessment of IgG level will be done by quantitative assessment of IgG in the serum of recovered persons by Chemiluminescence Immunoassay (CLIA).
Study NCT02321475 — intervention group
Intervention type: DRUG
Intervention: EGb761®
Study NCT04541615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Online course with proficiency test
Description: Participants will receive an online e-course with a proficiency test at the end. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
Study NCT04541615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Online course
Description: Participants will receive an online e-course but are not required to pass the proficiency test. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
Study NCT04541615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard training group
Description: After receiving a traditional lecture, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
Study NCT04541615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apprenticeship group
Description: Participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end. Participants will only receive papers on how the task will be performed and clinicians will help them with completion of the task.
Study NCT01239940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angioplasty using the paclitaxel-eluting balloon
Description: Balloon angioplasty
Study NCT01239940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angioplasty using the Everolimus-eluting stent
Description: Stent implantation
Study NCT03542617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT03542617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Solution
Study NCT02234193 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Micro biopsy
Description: This is a prospective, self-controlled study of the healing response after collecting micro skin biopsies of different sizes (from 200 µm to 2 mm in diameter) from up to seven 1.5 x 1.5 cm biopsy sites in pre-abdominoplasty skin areas that are scheduled for surgical removal. The collection procedure will be performed using similar techniques as standard skin biopsies: the skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, then micro biopsies of skin will be removed by biopsy punch/harvesting needle. No more than 10% of the skin area within each biopsy site will be collected. Tattoo ink as described will be applied to 4 micro-biopsies at the corners of each biopsy test site
Study NCT02234193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine with epinephrine
Description: The skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, prior to the surgical procedure
Study NCT01021527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment A
Description: No Treatment
Study NCT01021527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment B
Description: single dose administration of exenatide 5ug by subcutaneous injection
Study NCT00762385 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: galyfilcon A
Description: galyfilcon A
Study NCT00762385 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: comfilcon A
Study NCT01824875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO
Study NCT01824875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO
Study NCT01274078 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blueberries
Description: 150 grams of frozen blueberries on the same day as exercise
Study NCT01390129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: Deflated blood pressure cuff placed on upper arm for 30min
Study NCT01390129 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated before aortic clamping and repeated 3 times in total
Study NCT02000583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic group participants will engage in 150 minutes of aerobic exercise over 4-5 days per week for 52 weeks
Study NCT02000583 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Control group participants will be provided educational materials on starting an exercise program, but will receive no formal support for their exercise program.
Study NCT00470106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognitive skills training
Description: Group training on emotion perception, social perception, and understanding others' mental states.
Study NCT00470106 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hybrid intervention
Description: A combination of the two groups listed above.
Study NCT00470106 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: skills training
Description: Skills training in how to identify symptoms of illness and medication side effects.
Study NCT02170636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule E
Description: 50 mg BIBR 1048 MS
Study NCT02170636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule F
Description: 50 mg BIBR 1048 MS
Study NCT02170636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule G
Description: 50 mg BIBR 1048 MS
Study NCT02170636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Tablet H
Description: 50 mg BIBR 1048 MS
Study NCT02170636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Drinking solution
Description: 50 mg BIBR 1048 MS tartaric acid solution
Study NCT02138981 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemoembolization and Response-Dependent Resection
Description: patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
Study NCT02138981 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Resection
Description: patients received immediate surgical resection.
Study NCT00707447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREDIAS
Description: Group programme aiming at modification of lifestyle: lifestyle changes, 12 lesson a 90 minutes, delivered in a group setting, consists of analysis of barriers against lifestyle changes, behavior analysis of eating and exercise behavior, modification of unhealthy lifestyle and relapse prevention
Study NCT00707447 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Written Information about diabetes risks. Brochure about the value of a healthy lifestyle, calorie table, suggestions for healthy food and daily exercise
Study NCT01115855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily
Study NCT01115855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily or every once daily
Study NCT01279655 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: 20 min, 1mA, 8 weeks (5 days a week, 20 min a day)
Study NCT01279655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 20 min, 1mA, 8 weeks (5 days a week, 20 min a day)
Study NCT01279655 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Bimanual Training
Description: The training program consisted of a bimanual etch-a-sketch task. By rotating two wheels subjects have to match a line presented on the screen with the cursor. 8 weeks (5 days a week, 20 min a day)
Study NCT01279655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bimanual Training
Description: The training program consisted of a bimanual etch-a-sketch task. By rotating two wheels subjects have to match a line presented on the screen with the cursor. 8 weeks (5 days a week, 20 min a day)
Study NCT00466804 — intervention group
Intervention type: PROCEDURE
Intervention: Heart transplant
Description: People in this study will have a heart transplant and be monitored for signs of rejection
Study NCT02845726 — intervention group
Intervention type: OTHER
Intervention: Stent examination, urinary analysis, USSQ questionnaire
Study NCT04239482 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine + Nitrate / Nitrite
Description: Longer-term supplementation (8 weeks)
Study NCT04239482 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Longer-term supplementation (8 weeks)
Study NCT01658202 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: V0116 transdermal patch (Test treatment )
Study NCT01658202 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine transdermal patch (Reference Treatment )
Study NCT02170636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 40 mg Pantoprazole
Study NCT01689519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo supplied as tablets
Study NCT03652831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soft Tissue Mobilization with Neural Mobilization
Description: Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack for 10mints~* Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minute.~* Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization.~Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 50mints each session)
Study NCT03652831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soft Tissue Mobilization without Neural Mobilization
Description: * Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack for 10mints~* Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minutes Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 35mints each session)
Study NCT01637831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment completion of questionnaires assessing sleep and quality of life 1, 3 and 6 months after the start of effective CPAP treatment.
Study NCT02309853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual and tactile scanning training
Description: 20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space and trunk rotation. The intervention includes visual or tactile scanning training in three different spaces and will be individually adapted to the needs of the patients.~1. Visual or tactile scanning in the personal space~2. Visual or tactile scanning and trunk rotation in the peripersonal space~3. Visual scanning and trunk rotation in the extrapersonal space
Study NCT02309853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uni-modal visual scanning training
Description: 20 sessions of 30 minutes with traditional uni-modal visual scanning training in the peripersonal space.
Study NCT00698087 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MPL-Adjuvanted recombinant hepatitis B vaccine
Description: Intramuscular injection, 2 or 3 doses, 2 different formulations
Study NCT00698087 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Intramuscular injection, 2 or 3 doses
Study NCT01974076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS + CBT
Study NCT01974076 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS + CBT
Study NCT01376206 — intervention group
Intervention type: DRUG
Intervention: Fluticasone
Description: Collection of safety data